Peptide regulation in 2026: what actually changed

The dated record

1. September 19, 2025FDA approval

   Elamipretide (Forzinity) becomes the first FDA-approved mitochondria-targeted drug

   The FDA granted accelerated approval to elamipretide, a mitochondria-targeting peptide once known in research circles as SS-31, under the brand name Forzinity. The approval is narrow and specific: it is for Barth syndrome, a rare inherited mitochondrial disorder affecting roughly 150 people in the United States, to improve muscle strength in patients weighing at least 30 kg. It is the first FDA-approved drug that directly targets mitochondria. It is not approved, and was not studied for approval, as a longevity, anti-aging, or general performance treatment. Marketers who present this approval as validation of SS-31 for healthy-aging use are stretching a rare-disease label well past what it says.

   SS-31

   Sources: [1] [7]

2. February 27, 2026Announced (intent)

   HHS announces intent to move about 14 peptides back toward compounding access

   Health and Human Services Secretary Robert F. Kennedy Jr. announced that roughly 14 of the 19 peptides then sitting on the FDA's restricted Category 2 compounding list would be moved back to Category 1. The named set included BPC-157, thymosin alpha-1, TB-500, CJC-1295, ipamorelin, GHK-Cu, KPV, Semax, Selank and MOTS-c; Melanotan II, GHRP-2, GHRP-6, LL-37 and PEG-MGF were said to stay restricted. This is where the widely repeated "FDA restored access to 14 peptides" line comes from, and it is worth being precise about what it did and did not mean. It was an announcement of intent, not a completed rule. And moving a substance from Category 2 to Category 1 only governs whether a compounding pharmacy may prepare it while the FDA finishes its review; it is not FDA approval and does not establish proven safety, efficacy, or a standard dose.

   BPC-157Thymosin Alpha-1TB-500CJC-1295IpamorelinGHK-CuKPVSemaxSelankMOTS-c

   Source: [2]

3. April 15, 2026FDA action

   FDA removes a dozen peptides from Category 2, but does not place them in Category 1

   When the FDA actually acted, the result was murkier than the February announcement suggested. The agency removed a group of peptides from Category 2, including BPC-157, TB-500, MOTS-c, Epitalon, injectable GHK-Cu, KPV, Semax, LL-37, DiHexa, DSIP, PEG-MGF and Melanotan II. Crucially, it did not move them into Category 1 either. That left them in a transitional gray zone: no longer formally flagged as significant-safety-risk substances, but also not affirmatively cleared for compounding and still not FDA-approved drugs. Removal from the restricted list reduced a barrier; it did not, on its own, make these peptides legal to compound.

   BPC-157TB-500MOTS-cEpithalonGHK-CuKPVSemaxMelanotan II

   Source: [3]

4. April 2026Regulator probe

   UK's MHRA opens an investigation into peptide-clinic claims

   While US supply rules loosened, the UK moved the other way. The Medicines and Healthcare products Regulatory Agency opened an investigation into UK clinics making medicinal claims about peptides they cannot lawfully sell as medicines, naming BPC-157, thymosin alpha, and Cortexin among the compounds advertised with health benefits. The MHRA's position: if a clinic makes medicinal claims for a peptide injection, the product is treated as a medicine under the Human Medicines Regulations 2012 and the agency will act against clinics that breach the rules. The through-line for readers is that a peptide's legal status depends on where you are and on what claims are being made about it, and that most of these compounds still rest on preclinical or animal data.

   BPC-157Thymosin Alpha-1

   Source: [4]

5. July 23-24, 2026Advisory vote (nonbinding)

   FDA advisory committee recommends six of seven peptides for the 503A Bulks List

   The FDA's Pharmacy Compounding Advisory Committee met over two days and voted to recommend that six of the seven peptides it reviewed be added to the Section 503A Bulks List, the formal list of bulk substances that compounding pharmacies are permitted to use: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. The seventh, emideltide (also called DSIP), was not recommended. Reported tallies were close, including roughly 8-6 with one abstention for BPC-157 and 7-5 with one abstention for Epitalon, which was evaluated for insomnia. This is the strongest signal yet toward legal compounding access, but it changes nothing on its own: the committee's votes are nonbinding recommendations. Before any of these can lawfully be compounded, the Health Secretary must accept them and the FDA must complete formal notice-and-comment rulemaking, a process that can take more than a year. Until that finishes, these peptides remain not approved and not lawfully compoundable.

   BPC-157KPVTB-500MOTS-cEpithalonSemax

   Sources: [5] [6] [7]

Where each longevity peptide stands right now

As of August 24, 2026. "Not yet legal" means a pharmacy still cannot lawfully compound it until the FDA completes rulemaking, and it is not an FDA-approved drug in any case.

What this actually means for you

The honest read of 2026 is that the direction of travel in the US loosened, but far less, and far more slowly, than the headlines suggested. One peptide is a real approved drug, and only for a rare disease it was actually tested against. The rest are still research compounds whose compounding status is mid-process: an advisory committee has recommended six of them, which is a genuine milestone, but recommendation is not permission and permission is not approval. None of these movements added human efficacy evidence, changed a half-life, or established a safe dose. They changed paperwork. The compound pages in our library still carry the same cited science they did before any of this, which is the part that actually tells you whether something works.

Sources

1. [1]FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31Fight Aging! · October 2025
2. [2]The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually MeansPharmacy Times · February 27, 2026
3. [3]FDA Signals Major Shift on Peptides: Category 2 Removals Could Reshape Compounding LandscapeOptiMantra · April 2026
4. [4]MHRA investigates clinics following peptide claimsAesthetics Journal · April 2026
5. [5]FDA advisory committee nominates six peptides for pharmacies to compoundNational Community Pharmacists Association · July 31, 2026
6. [6]FDA Advisory Committee Endorses Compounding of Certain PeptidesHolland & Knight · August 2026
7. [7]July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · July 2026

A note on precision: this page deliberately separates what was approved from what was announced, acted on, recommended, or investigated, because those words carry very different weight and are constantly blurred elsewhere. If a claim here ever drifts from its source, the source wins - tell us and we will fix it.